Uciane Scarlett
Principal @ Oxford Science Enterprises
Cambridge, United States
Uciane Scarlett is a Series A investor at Oxford Science Enterprises in Cambridge focused on Biotechnology and Medical. Uciane Scarlett - Principal @ MPM Capital
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Uciane Scarlett invests in
Stages Uciane Scarlett invests in
Countries Uciane Scarlett invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 2 (50%)
- Health Care 1 (25%)
- Pharmaceutical 1 (25%)
- Clinical Trials 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Funding Round 1 (25%)
Country
- United Kingdom 2 (50%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic. | $112.5M / Aug 05, 2021 | ||
| T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies. T-Cypher’s integrated platform, D-Cypher, overcomes these challenges. | Seed / Dec 17, 2020 | ||
| PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic. | $45M / Series A / Dec 09, 2020 | ||
| Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives. | $50M / Series A / Apr 03, 2019 |
Co-Investors
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Oxford Science Enterprises Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexis Dormandy
Chief Executive Officer
|
|||
|
Alexis Zervoglos
Senior Partner (Technology)
|
|||
Claire Brown
Partner ( Life Sciences)
|
|||
Ekaterina Smirnyagina
Senior Partner and Head of Life Sciences
|
|||
David Norwood
Chairman
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Uciane Scarlett invest in?
Uciane Scarlett invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Uciane Scarlett?
Public channels for Uciane Scarlett include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Uciane Scarlett last invest?
The most recent investment recorded for Uciane Scarlett closed in Aug 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
